Merck (MRK) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MRK Merck & Co Inc MRK
72 GF Score
Price $127.63
GF Value $118.65
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Merck Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

MRK
72GF Score
Merck & Co Inc MRK
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Merck (MRK) Overvalued in 2026?

Based on GuruFocus' analysis, Merck stock appears to be overvalued. The current stock price of $127.63 is trading 7.6% above its estimated GF Value™ of $118.65. GuruFocus considers Merck to be Fairly Valued.

Key valuation signals for MRK:

  • Short Ratio:
  • GF Value™: $118.65 vs. price of $127.63 (7.6% above fair value)
  • GF Score™: 72/100 with 8 warning signs

No single metric tells the full story. See the MRK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Merck Business Description

Address 126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
72GF Score

Get the complete analysis for MRK

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$127.63
Price
$118.65
GF Value